IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week

• The findings could play a key role in guiding treatment choices, ImmunityBio said.
• ImmunityBio will present new research on intravesical recombinant BCG in patients who have not previously received BCG.
• Chairman Patrick Soon-Shiong will outline the role of IL-15 in urological cancers.

ImmunityBio is back on the retail radar after the biotech firm said it will present new data at the American Urological Association Annual Meeting next week, offering fresh insights into treatments for non-muscle-invasive bladder cancer.

At the time of writing, IBRX shares climbed 1.3% in pre-market trading.

IBRX’s Anktiva Plus BCG Data Takes Centrestage

The company will highlight cross-trial comparisons of its immunotherapy Anktiva plus Bacillus Calmette-Guérin (BCG) against other options, including Nadofaragene Firadenovec and Johnson & Johnson’s TAR-200.

With no direct head-to-head studies available, these analyses aim to help doctors better understand how different treatments compare in terms of effectiveness, durability, and safety, the company said. The findings could play a key role in guiding treatment choices, especially for patients whose disease no longer responds to standard BCG therapy.

ImmunityBio will also present new research on intravesical recombinant BCG (rBCG) in patients who have not previously received BCG. Additionally, the company plans to share updates on its ongoing registrational trial in BCG-naïve patients and efforts to improve access to BCG.

IBRX Chairman To Present Updates On Urological, Prostate Cancer Treatments

Meanwhile, Patrick Soon-Shiong, executive chairman of IBRX, will share updates on efforts to expand BCG access and advance research in BCG-naïve patients, while also outlining the role of IL-15 in urological cancers, including how it activates T cells and natural killer (NK) cells, current clinical data, and emerging combination strategies in bladder and prostate cancer.

The American Urological Association Annual Meeting will take place in Washington, DC, from May 15-18, 2026.

Anktiva’s Expanding Sales Boost IBRX’s Prospects

Preliminary first-quarter (Q1) net product revenue for Anktiva reached $44.2 million, marking a 168% jump from a year ago, while full-year 2025 revenue climbed to $113 million, a sharp increase from 2024.

The immunotherapy has also expanded its global footprint, recently gaining conditional approval across 27 EU countries, along with Iceland, Liechtenstein, and Norway, and launching commercially in Saudi Arabia.

IBRX Stock: How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier.

One user said, “Forward guidance of some sort would be helpful.”

Another user expects the stock to climb to $8. It is currently at $7.5.

IBRX stock has been a standout performer this year, gaining more than 250%.

Read also: UNH Stock Gains Retail Attention: This UnitedHealth Move Could Make Getting Treatment Faster

For updates and corrections, email newsroom[at]stocktwits[dot]com.